We are live on ! Find out more

2,936 hedge funds and large institutions have $95.2B invested in Pfizer in 2025 Q1 according to their latest regulatory filings, with 178 funds opening new positions, 1,287 increasing their positions, 1,202 reducing their positions, and 191 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% more funds holding in top 10

Funds holding in top 10: 4244 (+2)

7% more repeat investments, than reductions

Existing positions increased: 1,287 | Existing positions reduced: 1,202

0.02% more ownership

Funds ownership: 66.25%66.27% (+0.02%)

4% less capital invested

Capital invested by funds: $99.6B → $95.2B (-$4.39B)

7% less first-time investments, than exits

New positions opened: 178 | Existing positions closed: 191

2% less funds holding

Funds holding: 3,0012,936 (-65)

23% less call options, than puts

Call options by funds: $2.98B | Put options by funds: $3.87B

Holders
2,936
Holders Change
-65
Holders Change %
-2.17%
% of All Funds
39.29%
Holding in Top 10
44
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+4.76%
% of All Funds
0.59%
New
178
Increased
1,287
Reduced
1,202
Closed
191
Calls
$2.98B
Puts
$3.87B
Net Calls
-$895M
Net Calls Change
-$301M

PFE Hedge Fund Activity: Q1 2025 in Review

2,936 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q1 2025, worth a combined $95.2B — down 4.4% from $99.6B a quarter earlier.

Sellers outnumbered buyers: 191 funds closed out of PFE and 178 opened new positions — a net loss of 13 holders — while 1,202 trimmed existing stakes and 1,287 added.

The largest buyer was Fisher Asset Management, adding an estimated $950M. The largest seller was Charles Schwab, cutting an estimated $2.81B.

  • 2,936 institutional investors held Pfizer (PFE) as of Q1 2025, down from 3,001 in Q4 2024.
  • Funds reported $95.2B of Pfizer stock for Q1 2025, down 4.4% quarter-over-quarter.
  • 178 funds opened new Pfizer positions in Q1 2025 and 191 closed out, a net change of -13 holders.
  • The largest Pfizer buyer in Q1 2025 was Fisher Asset Management, an estimated $950M added.
  • The largest Pfizer seller in Q1 2025 was Charles Schwab, an estimated $2.81B sold.

Based on aggregated 13F filings for Q1 2025.